It has been reported that inhibiting autophagy during interleukin 2 (IL-2) immunotherapy can promote long-term tumor regression by tumor inhibition and enhance immune cell proliferation and infiltration (Liang et al., 2012). This evidence concerns the gene IL2 and neoplasm.